Mindset Pharma Inc has been added to a leading New York Stock Exchange-listed psychedelics exchange-traded fund.
The Toronto-based drug discovery firm announced its inclusion in the AdvisorShares Psychedelics ETF, which trades on the NYSE Arca under the symbol ‘PSIL.’
The ETF is an actively managed product that invests in the flourishing psychedelic drugs industry.
READ: Mindset Pharma says further preclinical results for its MSP-4018 drug candidate demonstrate strong efficacy and improved safety profile
Mindset is focused on creating optimized and patentable next-generation psychedelic drugs to treat psychiatric disorders.
The fund only holds companies that are seen as “leading the way” in the psychedelics industry, according to a statement from Mindset.
CEO James Lanthier told investors that the company’s inclusion in the actively-managed PSIL is “another positive step in building awareness and education” about the company, as well as the psychedelics industry as a whole.
“We are thrilled to be considered a leader in the space and appreciate the support from the capital markets as we progress our differentiated pipeline of next-generation psychedelic-inspired drug candidates towards the clinic,” Lanthier said.
Mindset is hoping to progress its lead drug candidate MSP-1014, a psilocybin analog, into clinical trials by the end of 2022.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas